Water → 5-[(3As,4s,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl]-n-(4-{[3-[2-(cyclopentylamino)-pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino}butyl)-pentanamide
Reaction equation
[CH:1]1([NH:6][C:7]2[N:12]=[C:11]([C:13]3[C:14]([C:28]4[CH:33]=[CH:32][C:31]([O:34][CH3:35])=[CH:30][CH:29]=4)=[N:15][N:16]4[C:21]([NH:22][CH2:23][CH2:24][CH2:25][CH2:26][NH2:27])=[CH:20][CH:19]=[CH:18][C:17]=34)[CH:10]=[CH:9][N:8]=2)[CH2:5][CH2:4][CH2:3][CH2:2]1.C(N(CC)CC)C.C1C(=O)N([O:50][C:51]([CH2:53][CH2:54][CH2:55][CH2:56][C@@H:57]2[S:61][CH2:60][C@@H:59]3[NH:62][C:63]([NH:65][C@H:58]23)=[O:64])=O)C(=O)C1.O>CN(C)C=O>[O:64]=[C:63]1[NH:62][C@H:59]2[CH2:60][S:61][C@@H:57]([CH2:56][CH2:55][CH2:54][CH2:53][C:51]([NH:27][CH2:26][CH2:25][CH2:24][CH2:23][NH:22][C:21]3[N:16]4[N:15]=[C:14]([C:28]5[CH:29]=[CH:30][C:31]([O:34][CH3:35])=[CH:32][CH:33]=5)[C:13]([C:11]5[CH:10]=[CH:9][N:8]=[C:7]([NH:6][CH:1]6[CH2:2][CH2:3][CH2:4][CH2:5]6)[N:12]=5)=[C:17]4[CH:18]=[CH:19][CH:20]=3)=[O:50])[C@H:58]2[NH:65]1Participants
Reactant 4
Product 1
Reagents, catalysts & solvents 1
Procedure
To a cold (0° C.) solution of N-[3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]butane-1,4-diamine (33 mg, 0.07 mmol) in N,N-dimethylformamide (3 mL) was added triethylamine (0.03 mL, 0.21 mmol) and d-biotin-N-hydroxysuccinimide ester (27 mg, 0.08 mmol). The resultant mixture was warmed to room temperature and stirred for 30 minutes. A subsequent 5 mg of d-biotin-N-hydroxysuccinimide ester was added and the mixture was stirred an additional 30 minutes. Water was added and the layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and then brine. The aqueous layer was extracted with dichloromethane and the combined organics were dried over sodium sulfate. Filtration and concentration followed by flash chromatography (5% to 8% methanol in dichloromethane) provided 5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-N-(4-{[3-[2-(cyclopentylamino)-pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino}butyl)-pentanamide (25 mg, 51%) as a yellow solid. 1H NMR (CDCl3): δ 7.98 (d, 1 H), 7.80 (d, 1 H), 7.58 (d, 2 H), 7.32 (m, 1 H), 7.00 (d, 2 H), 6.60 (s,1 H), 6.39 (m, 1 H), 6.33 (d, 1 H), 6.18 (m, 1 H), 6.02 (m, 1 H), 5.72 (s, 1 H), 5.62 (broad, 1 H), 4.44–4.31 (m, 2 H), 4.19 (m, 1 H), 3.89 (s, 3 H), 3.39 (m, 2 H), 3.28 (m, 2 H), 3.06 (m, 1 H), 2.95 (m, 2 H), 2.77 (dd, 1 H), 2.58 (d, 1 H), 2.20–2.05 (m, 4 H), 1.82–1.54 (m, 12 H), 1.39 (m, 2 H); MS m/z 698 (M+1).
Workup
- stirringthe mixture was stirred an additional 30 minutes
- customthe layers were separated
- washThe organic layer was washed with saturated aqueous sodium bicarbonate
- extractionThe aqueous layer was extracted with dichloromethane
- dry with materialthe combined organics were dried over sodium sulfate
- filtrationFiltration and concentration
Sources & evidence
- ORD record
- ord-f1866283030c4ddb819d4d99b87ef169
- Source dataset
- uspto-grants-2006_12
- Patent number
- US07153855B2
Reaction notes
Loading…